Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma

A novel treatment strategy for resectable cutaneous squamous cell carcinoma (CSCC) utilizing neoadjuvant pembrolizumab allows patients to avoid surgery and radiotherapy. The De-Squamate study, led by Rahul Ladwa, MBChB, MPhil, revealed that 63% of participating patients achieved a complete response from just four cycles of pembrolizumab. The trial emphasized the importance of multimodal response assessment and suggested that immunotherapy could serve as a strong alternative to traditional surgical interventions, thus ensuring better disease-free survival outcomes.